-
Je něco špatně v tomto záznamu ?
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
F. Onida, G. Sbianchi, A. Radujkovic, K. Sockel, N. Kröger, J. Sierra, G. Socié, J. Cornelissen, X. Poiré, L. Raida, JH. Bourhis, J. Finke, J. Passweg, U. Salmenniemi, HC. Schouten, Y. Beguin, S. Martin, E. Deconinck, A. Ganser, S. Zver, B....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- chronická myelomonocytární leukemie * MeSH
- lidé MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.
CHU de Lille Univ Lille Infinite INSERM U1286 59000 Lille France
CHU of Liege and University of Liege Liege Belgium
Cliniques Universitaires St Luc Brussels Belgium
Department of Biology Tor Vergata University Rome Italy
Department of Haematology Trinity College Dublin St James's Hospital Dublin 8 Ireland
EBMT Data Office Leiden Leiden The Netherlands
Erasmus MC Cancer Institute Rotterdam The Netherlands
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan Milan Italy
Gustave Roussy Institut de Cancérologie Val de Marne Villejuif France
Hannover Medical School Hannover Germany
Hospital Jean Minjoz Besancon France
Hospital Santa Creu i Sant Pau Barcelona Spain
Hospital St Louis Paris France
Nottingham University Nottingham UK
Nouvel Hopital Civil Strasbourg France
Robert Bosch Krankenhaus Stuttgart Germany
Turku University Hospital Turku Finland
University Hospital Basel Basel Switzerland
University Hospital Dresden TU Dresden Dresden Germany
University Hospital Eppendorf Hamburg Germany
University Hospital Maastricht Maastricht The Netherlands
University Medical Center Ljubljana Slovenia
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018108
- 003
- CZ-PrNML
- 005
- 20220804134548.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-021-01555-9 $2 doi
- 035 __
- $a (PubMed)35352038
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Onida, Francesco $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milan, Italy. francesco.onida@unimi.it $1 https://orcid.org/0000000229913474
- 245 10
- $a Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP / $c F. Onida, G. Sbianchi, A. Radujkovic, K. Sockel, N. Kröger, J. Sierra, G. Socié, J. Cornelissen, X. Poiré, L. Raida, JH. Bourhis, J. Finke, J. Passweg, U. Salmenniemi, HC. Schouten, Y. Beguin, S. Martin, E. Deconinck, A. Ganser, S. Zver, B. Lioure, R. Rohini, L. Koster, P. Hayden, S. Iacobelli, M. Robin, I. Yakoub-Agha
- 520 9_
- $a Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická myelomonocytární leukemie $7 D015477
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sbianchi, Giulia $u Department of Biology, Tor Vergata University, Rome, Italy
- 700 1_
- $a Radujkovic, Aleksandar $u University of Heidelberg, Heidelberg, Germany $1 https://orcid.org/0000000285435016
- 700 1_
- $a Sockel, Katja $u University Hospital Dresden, TU Dresden, Dresden, Germany
- 700 1_
- $a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
- 700 1_
- $a Sierra, Jorge $u Hospital Santa Creu i Sant Pau, Barcelona, Spain $1 https://orcid.org/0000000279660356
- 700 1_
- $a Socié, Gerard $u Hospital St. Louis, Paris, France $1 https://orcid.org/0000000221147533
- 700 1_
- $a Cornelissen, Jan $u Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- 700 1_
- $a Poiré, Xavier $u Cliniques Universitaires St. Luc, Brussels, Belgium $1 https://orcid.org/0000000318970227
- 700 1_
- $a Raida, Luděk $u Department of Hemato-Oncology-Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Bourhis, Jean Henri $u Gustave Roussy, Institut de Cancérologie, Val-de-Marne, Villejuif, France
- 700 1_
- $a Finke, Jürgen $u University of Freiburg, Freiburg, Germany
- 700 1_
- $a Passweg, Jakob $u University Hospital, Basel, Basel, Switzerland
- 700 1_
- $a Salmenniemi, Urpu $u Turku University Hospital, Turku, Finland
- 700 1_
- $a Schouten, Harry C $u University Hospital Maastricht, Maastricht, The Netherlands
- 700 1_
- $a Beguin, Yves $u CHU of Liege and University of Liege, Liege, Belgium
- 700 1_
- $a Martin, Sonja $u Robert-Bosch-Krankenhaus, Stuttgart, Germany $1 https://orcid.org/0000000181816834
- 700 1_
- $a Deconinck, Eric $u Hospital Jean Minjoz, Besancon, France
- 700 1_
- $a Ganser, Arnold $u Hannover Medical School, Hannover, Germany
- 700 1_
- $a Zver, Samo $u University Medical Center, Ljubljana, Slovenia $1 https://orcid.org/0000000329327923
- 700 1_
- $a Lioure, Bruno $u Nouvel Hopital Civil, Strasbourg, France
- 700 1_
- $a Rohini, Radia $u Nottingham University, Nottingham, UK
- 700 1_
- $a Koster, Linda $u EBMT Data Office Leiden, Leiden, The Netherlands
- 700 1_
- $a Hayden, Patrick $u Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland $1 https://orcid.org/0000000313744503
- 700 1_
- $a Iacobelli, Simona $u Department of Biology, Tor Vergata University, Rome, Italy
- 700 1_
- $a Robin, Marie $u Hospital St. Louis, Paris, France $1 https://orcid.org/0000000313889876
- 700 1_
- $a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ Lille, Infinite, INSERM U1286, 59000, Lille, France $1 https://orcid.org/0000000345248782
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 57, č. 6 (2022), s. 896-902
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35352038 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134542 $b ABA008
- 999 __
- $a ok $b bmc $g 1821938 $s 1169351
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 57 $c 6 $d 896-902 $e 20220329 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20220720